CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 71 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-10-03 | Haddadin Yezan Munther Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-10-03 | Haddadin Yezan Munther Director | Grant or award · Stock Option (Right to Buy) | +80,176 | $0.99 | $79K | 80,176 |
| 2019-10-03 | Thomas Joe Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-10-03 | Thomas Joe Director | Grant or award · Stock Option (Right to Buy) | +48,207 | $0.99 | $47K | 48,207 |
| 2019-10-03 | Sukhtian Faisal Ghiath Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-10-03 | Sukhtian Faisal Ghiath Director | Grant or award · Stock Option (Right to Buy) | +86,772 | $0.99 | $85K | 86,772 |
| 2019-10-03 | THURMAN RANDY H Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-10-03 | THURMAN RANDY H Director | Grant or award · Stock Option (Right to Buy) | +207,036 | $0.99 | $204K | 207,036 |
| 2019-10-03 | HILZINGER KURT J Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-10-03 | HILZINGER KURT J Director | Grant or award · Stock Option (Right to Buy) | +60,893 | $0.99 | $60K | 60,893 |
| 2019-09-30 | BioLexis Pte Ltd. Director | Other acquisition · Series A-1 Convertible Preferred Stock | +1,620 | 66,451 | ||
| 2019-09-18 | KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy | Sale | −1,350 | $1.70 | $2K | 8,926 |
| 2019-09-18 | KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy | Sale | −1,350 | $1.70 | $2K | 80,863 |
| 2019-09-12 | KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2019-06-30 | BioLexis Pte Ltd. Director | Other acquisition · Series A-1 Convertible Preferred Stock | +1,581 | 64,831 | ||
| 2019-06-17 | BioLexis Pte Ltd. Director | Option exercise | +2,181,818 | 14,039,494 | ||
| 2019-06-17 | BioLexis Pte Ltd. Director | Option exercise · Warrant (Right to Buy) | −3,636,364 | 0 | ||
| 2019-04-12 | BioLexis Pte Ltd. Director | Grant or award | +3,636,364 | $2.75 | $10.0M | 11,857,676 |
| 2019-04-12 | BioLexis Pte Ltd. Director | Grant or award · Warrant (Right to Buy) | +3,636,364 | 3,636,364 | ||
| 2019-04-12 | BioLexis Pte Ltd. Director | Grant or award · Warrant (Right to Buy) | +3,636,364 | 3,636,364 |
Page 13 of 14 · 276 trades